Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
-
Tan CR, Usmani S, Derkach A, de Meneze Silva Corraes A, Parrondo R, Ailawadhi S, Asoori S, Dave M, Popat R, Morjaria O, Hajek R, Mihalyova J, Htut M, Janakiram M, Visram A, Kastritis E, Dimopoulos MA, Mart?nez-L?pez J, Nagarajan C, Bal S, Costa LJ, Einsele H, Steinbrunn T, Waldschmidt JM, Riedhammer C, Banerjee R, Chng WJ, Tso A, Lin Y, Martin T, Mian H. Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis. Blood Adv. 2026 May 12; 10(9):2937-2946.
-
Wood WA, Kumar SK, Semmel EA, James S, Schroeder MA, Chung DJ, Rosenberg A, Zonder J, Rubinstein S, D'Souza A, Martin T, Chari A, Vij R, Nooka AK, Anderson KC, Neuberg DS, Richard S, Torres K, Weiss BM, Pederson L, Derkach A, Geyer S, Usmani SZ. Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma. Blood Adv. 2026 May 12; 10(9):3094-3102.
-
Maclachlan KH, Tan CR, Shekarkhand T, Rueda C, Derkach A, Hashmi H, Hassoun H, Shah UA, Hultcrantz M, Lesokhin AM, Mailankody S, Maura F, Merz M, Firestone R, Jurgens EM, Miller KC, Rajeeve S, Giralt S, Shah GL, Scordo M, Landau HJ, Zhang Y, Cimera R, Arcila ME, Korde N, Usmani SZ. IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM. Blood Adv. 2026 Apr 28; 10(8):2616-2625.
-
Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson L, Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mirza AS, Mohan M, Narra R, Rosko AE, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, Patel KK. Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. Blood Cancer J. 2026 Apr 14; 16(1).
-
Hashmi H, Sebastian T, Rajeeve S, Farzana T, Firestone RS, Jurgens EM, Miller KC, Maura F, Lesokhin AM, Tan CR, Shah GL, Korde N, Landau HJ, Merz M, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz ML, Derkach A, Nemirovsky D, Giralt S, Mailankody S, Usmani SZ. Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma. Blood Cancer J. 2026 Apr 12; 16(1).
-
Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S, Tang H, Owens RW, Sevcikova T, Fonseca R, Durante M, Diamond B, Zhao L, Zhu YX, Shi CX, Matulis SM, Mitsiades CS, Landgren O, Usmani S, Hajek R, Chesi M, Bergsagel PL, Braggio E, Boise LH, Fonseca R, Kumar S, Maura F, Baughn LB. Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH). Blood. 2026 Apr 02; 147(14):1598-1610.
-
Shah UA, Cogrossi LL, Garc?s JJ, Policastro A, Castro F, Derkach A, Fei T, DeWolf S, Grioni M, Sisti S, Blaslov J, Adintori PA, Hosszu KK, McAvoy D, Baichoo M, Cross JR, Paredes J, Anuraj A, Raj SS, Pohl C, Zordan P, Zinsmeyer V, Jesus Faustino Ramos RJ, Lorenzoni M, Gipson B, Maclachlan KH, Gradissimo A, Boiocchi L, Aleynick N, Marchigiani C, Pagani S, Salehi E, Koche RP, Chaligne R, Block T, Korde N, Tan CR, Hultcrantz M, Hassoun H, Shah GL, Scordo M, Lahoud OB, Chung DJ, Landau HJ, Peled JU, Clementi N, Chesi M, Bergsagel PL, Mailankody S, Pollak MN, D'Souza A, Landgren O, Chimonas S, Giralt SA, Usmani SZ, Iyengar NM, Lesokhin AM, van den Brink MRM, Bellone M. A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model. Cancer Discov. 2026 Apr 01; 16(4):697-720.
-
Suzuki K, Matsumoto M, Takamatsu H, Kosugi H, Kondo T, Fujisaki T, Facon T, Zweegman S, Ito M, Sakai C, Kanai S, Nakatogawa T, Rowe M, Carson R, Usmani SZ. Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial. Int J Hematol. 2026 Jul; 124(1):104-113.
-
Hamadeh IS, Merz M, Derkach A, Modelevsky L, Lesokhin AM, Mailankody S, Hultcrantz ML, Tan CR, Hassoun H, Shah UA, Maclachlan K, Rajeeve S, Hashmi H, Maura F, Firestone RS, Wang AX, Amin A, Patel D, Scordo M, Shah GL, Landau HJ, Giralt S, Usmani SZ, Korde N. Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies. Clin Lymphoma Myeloma Leuk. 2026 Jun; 26(6):e802-e810.
-
Malik MA, Dalvi AA, Derkach A, Mart?nez JA, Hydren JR, Merlo G, Aldana AM, Ahlstrom JM, Usmani SZ, Chimonas S, Ortiz R, Shah UA. Diagnosis Disclosure and Related Illness Experience in Patients With Multiple Myeloma and Precursor Plasma Cell Disorders. Clin Lymphoma Myeloma Leuk. 2026 Jun; 26(6):e793-e801.e4.